Penumbra price target raised to $325 from $303 at Citi

Citi analyst Joanne Wuensch raised the firm’s price target on Penumbra to $325 from $303 and keeps a Buy rating on the shares. Most Q4 results in medical technology met expectations, which bodes well for the sector, the analyst tells investors in a research note. The analyst says the group has historically "worked" in a beat and raise environment and historically has been "recessionary resistant." Citi removed Penumbra from its "Top Picks" given the stock’s 25% year-to-date rally.